# Life Science and Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/life-science-and-technology

- Industry: Healthcare IT
- Headquarters: Shanghai, China
- Website: www.shlifestemcell.com
- Total disclosed funding: $2.3M
- Latest round: Series A (Mar 22, 2016)
- Investors on record: 1

## About

Life Science and Technology specializes in cell and gene therapies, focusing on innovative treatments for severe medical conditions. Their work includes advanced research and development to address critical healthcare needs.Founded in 2013 by Baowen Chen, Life Science and Technology operates out of Shanghai, China, where it engages in the research and development of innovative cell and gene therapies. The company has raised CNY 15 million in its Series A funding round on March 22, 2016, from Langsheng Investment. The organization has not undergone any significant pivots or changes in business operations since its inception and has a singular deal recorded in its history.Shanghai Life Sciences Technology Co., Ltd. specializes in the discovery, research, development, and manufacturing of innovative cell and gene therapies (CGT). The company's core offerings include a range of cell-based and gene-based treatments designed to address severe medical conditions with significant treatment limitations, such as idiopathic pulmonary fibrosis, diabetes-related kidney disease, and various types of solid tumors. Utilizing advanced technologies such as the LF-ToolBox platform, the company provides comprehensive solutions for drug development, including molecular cloning tools and stable lentiviral vectors. These products are targeted toward healthcare providers, research institutions, and hospitals across various geographical markets, including major regions in Asia and potentially extending into North America and Europe as the company scales its operations.Shanghai Life Sciences Technology Co., Ltd. generates revenue primarily through collaborations and partnerships with academic institutions and healthcare organizations. The transaction structure typically involves B2B agreements where the company offers its specialized products and services directly to hospitals and research entities, facilitating clinical trials and treatment applications. Pricing models are based on the nature of the service, which may include fees for clinical trial support, product supply, and technological licensing agreements for their proprietary CGT platform. Notably, the firm’s flagship therapies, such as LF-MSC-GT010 and LF-CAR series products, serve as critical components in their revenue model, reflecting their commitment to developing effective treatment options in the biopharmaceutical landscape.Life Science and Technology plans to leverage its recent Series A funding of CNY 15 million to enhance its product offerings and expand into new geographical markets. Specifically, the company aims to introduce new cell and gene therapy products over the next few years, targeting markets in North America and Europe by 2025. This expansion will be supported by the advanced technologies being developed through their LF-ToolBox platform, ensuring a comprehensive suite of solutions for healthcare providers. The company is focused on solidifying partnerships with more hospitals and research institutions to facilitate clinical trials and expand its treatment applications.

## Funding rounds

- Series A, Mar 22, 2016, $2.3M — Langsheng Investment

## Investors

- Langsheng Investment (https://capitalatlas.ai/funds/langsheng-investment) — Series A